泌尿器科領域の出血に対するAC-17使用経験
スポンサーリンク
概要
- 論文の詳細を見る
A new intravenouslya dministeredh emostaticc al l e dA C-17(a drenochromeder ivative)i s utilized in this clinical study. This material is soluble in water, hence it is not necessary to be prepared by using sodium salicylate as a solubilizing agent. The patient was given 10 mg of AC-17 intramuscularly or intravenously every eight to twelve hours, and some cases were given postoperatively5 % glucose solution containing3 0-50m g of AC-17in travenously. This drug was used pre- and postoperatively in 61 cases of urological surgery (16 cases of nephrectomy1, 6 cases of retropubic prostatectomy,8 cases of nephrolithotomy andt he others), and bleedingi n operationa nd postoperativeh ematuria are inhibited Nine patients of so-callede ssential hematuria were treated with AC-1 7 a, nd in 4 cases hematuriad isappeared.
- 泌尿器科紀要刊行会の論文
泌尿器科紀要刊行会 | 論文
- MVAC療法後の転移性尿路上皮癌に対するGemcitabine, Docetaxel, Carboplatin併用化学療法の検討
- Grade 3 Ta-1表在性膀胱癌に対する膀胱温存治療
- 腹腔鏡下に摘出した後腹膜神経線維腫の1例
- 移植腎生検による腎内動脈瘤破裂の1例
- Modified M-VAC療法後に残存腫瘍切除を施行した進行尿路上皮癌患者の治療成績